Ceribell, Inc. (CBLL) stock
CBLLNasdaqElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 6/30150% above fair value
$26.35−1.45 (-5.22%)
Close on Nov 12, 2026Market cap $1.01BP/E –Yield –
Ceribell ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Ceribell's ebitda for the twelve months ending Jun 30, 2026 was -$68.95M. For fiscal 2025 it was -$57.06M.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$57.06M | – |
| FY2024 | Dec 31, 2024 | -$38.57M | – |
| FY2023 | Dec 31, 2023 | -$29.19M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$19.78M | – |
| Q1 FY2026 | Mar 31, 2026 | -$20.51M | – |
| Q4 FY2025 | Dec 31, 2025 | -$14.31M | – |
| Q3 FY2025 | Sep 30, 2025 | -$14.35M | – |
| Q2 FY2025 | Jun 30, 2025 | -$14.75M | – |
| Q1 FY2025 | Mar 31, 2025 | -$13.87M | – |
| Q4 FY2024 | Dec 31, 2024 | -$12.52M | – |
| Q3 FY2024 | Sep 30, 2024 | -$9.77M | – |
| Q2 FY2024 | Jun 30, 2024 | -$8.27M | – |
| Q1 FY2024 | Mar 31, 2024 | -$8.20M | – |
| Q4 FY2023 | Dec 31, 2023 | -$8.15M | – |
| Q3 FY2023 | Sep 30, 2023 | -$6.99M | – |
See a number that looks wrong?